VC-backed Rgenix appoints new chief medical officer
New York City-based Rgenix Inc, a developer of first-in-class small molecule and antibody cancer therapeutics, has named Dr. Robert Wasserman as its new chief medical officer. Recently, Wasserman was chief medical officer at Toronto-based Northern Biologics, a developer of first-in-class immuno-oncology products. Rgenix's backers include Lepu Medical, Oceanpine Capital, WuXi AppTec’s Corporate Venture Fund, Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments LLC and the Partnership Fund for New York City.
16 September 2019•5 mins read
